Pulmonary function testing (PFT) is a vital diagnostic tool in respiratory medicine, providing a comprehensive evaluation of lung function. However, interpreting the results can be complex for healthcare professionals due to the plethora of data and the intricacies of lung physiology. This article aims to demystify the process of PFT interpretation.
Key parameters in PFT include Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1), and the FEV1/FVC ratio. FVC reflects the maximum amount of air a patient can exhale forcefully after maximal inhalation, while FEV1 indicates the volume exhaled in the first second. The FEV1/FVC ratio is essential to distinguish between obstructive and restrictive lung disease.
A decreased FEV1/FVC ratio (<70%) indicates obstructive lung disease, such as asthma or COPD. In contrast, a restrictive pattern is suggested by a normal or increased FEV1/FVC ratio with reduced FVC. Conditions like pulmonary fibrosis and muscular dystrophy typically present this pattern.
Severity grading is based on the degree of reduction in FEV1. Mild obstruction is characterized by FEV1 ≥ 80% of the predicted value, moderate by 50-79%, severe by 30-49%, and very severe by <30%. In restrictive diseases, severity is often assessed by the degree of reduction in Total Lung Capacity (TLC).
Bronchodilator responsiveness testing can differentiate between asthma and COPD. A positive response, indicated by an increase in FEV1 or FVC by ≥12% and ≥200ml following bronchodilator administration, suggests asthma.
Interpreting PFT results is a nuanced process that requires understanding of lung physiology and the various parameters involved. By mastering these concepts, healthcare professionals can make accurate diagnoses, assess disease severity, and guide appropriate management of respiratory conditions.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation